Business Of Biotech cover image

Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD

Business Of Biotech

00:00

The Future of Vincirix

Our VIP 943 is going in the clinic right now. Next year, we're planning our CXER5 antibody drug conjugate. We have a very unique linker and the capability of different types of linkers. So there's more to build into our pipeline that we are currently working on.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app